-
Product Insights
Camino
Camino is a Hydro project located in California, United States. The project is owned by Sacramento Municipal Utility District. The project came online in 1963. Empower your strategies with our Camino report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on...
-
Product Insights
Camino Rojo Project
The Camino Rojo Project is a gold mine in Mexico. It is currently in operation. Empower your strategies with our Camino Rojo Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain...
-
Product Insights
Camino Solar PV Park
Camino Solar PV Park is a solar PV project located in California, United States. The project is owned and being developed by Avangrid Renewables LLC. The project is at the permitting stage. Empower your strategies with our Camino Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UBX-1325 in Diabetic Macular Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UBX-1325 in Diabetic Macular Edema report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UBX-1325 in Diabetic Macular Edema Drug Details: UBX-1325 is under development...
-
Product Insights
Smoking Cessation – Drugs In Development, 2023
Global Markets Direct’s, ‘Smoking Cessation - Drugs In Development, 2023’, provides an overview of the Smoking Cessation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Major Depressive Disorder – Drugs In Development, 2023
Global Markets Direct’s, ‘Major Depressive Disorder - Drugs In Development, 2023’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBP-0069330 in Smoking Cessation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SBP-0069330 in Smoking Cessation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SBP-0069330 in Smoking Cessation Drug Details: SBP-0069330 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SBP-0069330 in Substance (Drug) Abuse
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.SBP-0069330 in Substance (Drug) Abuse Drug Details:SBP-0069330 is under development for the treatment of substance abuse...